PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

SGLT2 versus DPP-4 Inhibitors: Modest Glycemic Edge, Consistent Weight Benefit

SGLT2 inhibitorsDPP-4 inhibitorsempagliflozincanagliflozindapagliflozinertugliflozinsitagliptinlinagliptintype 2 diabetesHbA1cweight lossgenital infectionmeta-analysisglycemic control Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors excel in control but risk infections.

Selecting appropriate glucose-lowering drugs is essential for individualized patient care in type 2 diabetes, balancing efficacy with safety concerns. High-dose sodium-glucose linked transporter 2 inhibitors (SGLT2i) demonstrated superior glycemic control compared to dipeptidyl peptidase 4 inhibitors (DPP4i), and all SGLT2i doses were more effective in weight reduction, but they increased genital infection risk. While high-dose SGLT2i offer better glycemic control, they pose a higher infection risk; clinicians must tailor therapy based on individual patient profiles and priorities. SGLT2i offer more effective glycemic control and weight loss than DPP4i but increase the risk of genital infections.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Fang X, Li R, Liu S, Zou X, Zhong Y, Yang Y

Citation: Fang X, Li R, Liu S, et al. SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. Frontiers in endocrinology. 2026;17:1930813. doi:10.3389/fendo.2026.1930813

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.